GlobeNewswire·Nov 3, 2026, 9:00 AM ET

BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026

BriaCell Therapeutics Corp. & its subsidiary BriaPro announced four preclinical research presentations at the SITC 41st Annual Meeting in Phoenix, AZ, from November 4-8, 2026.
Bria-OTS+ studies demonstrated immune-cell activation & tumor-cell killing across breast, prostate, & lung cancer models using a genetically engineered whole-cell vaccine platform.
Bria-OTS+ activated innate & adaptive immune cells, including dendritic, NK, NKT, CD4+ T, & CD8+ T cells, & induced responses in patient-derived PBMCs.
BriaPro's BP-80 (soluble CD80-Fc fusion protein) showed CD28 co-stimulatory activity & CTLA-4 inhibition counteraction in cell assays.
Nonhuman primate studies for BP-80 revealed a no observed effect level (NOEL) of 50 mg/kg/day & a half-life ranging from 8.08 to 8.92 hours.
TILsRx-001, a tumor-targeted checkpoint inhibitor, utilized engineered CD80 with enhanced PD-L1 affinity & an anti-B7-H3 scFv to reactivate tumor-infiltrating lymphocytes.
Molecular design efforts produced CD80 variants with over 130-fold stronger PD-L1 binding than wild-type while preserving CD28 affinity.
Another CD80 variant mutation increased CTLA-4 affinity approximately fivefold while maintaining CD28 binding capabilities.